Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Apr;11(4):541–542. doi: 10.4103/1673-5374.180727

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Neural Regeneration Research

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

PMC Copyright notice

Currently available clinical application of zonisamide for epilepsy and Parkinson's disease, and its potential repositioning for nerve injuries, neuropathies, and neuromuscular disorders.

Zonisamide is an anti-epileptic agent that has been successfully repositioned for Parkinson's disease. We report that zonisamide can be potentially repositioned again for peripheral nerve injuries, neuropathies, and neuromuscular disorders. Pharmacological mechanisms of zonisamide for each disease are indicated in bullet statements. ALS: Amyotrophic lateral sclerosis; Bdnf: brain-derived neurotrophic factor; Erk1/2: extracellular signal-regulated protein kinases 1 and 2; MAO-B: monoamine oxidase B; Ngf: nerve growth factor; Ntf4: neurotrophin 4; Ntrk1: neurotrophic tyrosine kinase receptor type 1; Ntrk2: neurotrophic tyrosine kinase receptor type 2.